For TNM stage is a well-accepted marker for the prognosis of HCC [2, 6], our Kaplan- Meier analysis also found that the HCC patients with low EGFL8 expression had worse overall survival and progression free survival than those with high EGFL8 expression, suggesting EGFL8 as a potential prognostic biomarker for HCC, which, of cause, should be further verified in the future studies. The gene discussed is EGFL8; the disease is hepatocellular carcinoma.